♥
ISIN : INE048B01027
NSE : JAGSNPHARM
BSE : 507789
Face Value : 5
Industry : Pharmaceuticals & Drugs
EPS : 8.46
EPS (TTM) : 8.96
Price to Earning (P/E) : 25.67
Book Value : 64.43
Price to Bookvalue (P/B) : 3.37
Dividend Yield : 2 %
Return on Equity (ROE) : 14.02 %
Return on Capital Employed (ROCE) : 17.72 %
Jagsonpal Pharmaceuticals Limited
ISIN : INE048B01027
NSE : JAGSNPHARM
BSE : 507789
Face Value : 5
Industry : Pharmaceuticals & Drugs
EPS : 8.46
EPS (TTM) : 8.96
Price to Earning (P/E) : 25.67
Book Value : 64.43
Price to Bookvalue (P/B) : 3.37
Dividend Yield : 2 %
Return on Equity (ROE) : 14.02 %
Return on Capital Employed (ROCE) : 17.72 %
Jagsonpal Pharmaceuticals share price(02-Apr-2026) | |
|---|---|
| Open / Close | 0 - 0 NAN % |
| Low / High | 0 - 0 NAN % |
| Trade Volume | 0 |
| 52 Week Low / High | 0 - 0 NAN % |
| Open / Close | 184.45 - 186.2 0.9 % |
| Low / High | 184 - 187 1.6 % |
| Trade Volume | 3,990 |
| 52 Week Low / High | 154.9 - 301.8 94.8 % |
-
YOU MAY ALSO LIKE
- High dividend stocks
High dividend yield stocks on Stock exchange NSE and BSE - How much money do you need to retire
Know how much money do you need to retire, before how much to invest ? - Share Market basics for beginners
Share Market jargons in simple terms - Low PE ratio stocks
Undervalued, low PE ratio stocks on Stock exchange NSE and BSE - CAGR Calculator
Check your investment returns using our CAGR / Investment Growth Calculator - Stock market course tutorial
Stock Market Investment Course explained in simple words.
CONSOLIDATED QUARTERLY RESULT FOR JAGSONPAL PHARMACEUTICALS LIMITED
| Date End | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| No of months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months |
| Net Sales | 605.97 | 605.26 | 601.4 | 554.51 | 601.53 | 578.29 | 472.34 | 434.86 | 614.39 | 746.92 |
| Total Income | 609.1 | 616.47 | 618.81 | 580.1 | 621.5 | 601.03 | 497.55 | 459.73 | 628.83 | 763.46 |
| Total Expenditure | 541.79 | 476.25 | 515.06 | 500.14 | 515.16 | 494.64 | 438.38 | 408.17 | 512.01 | 584.07 |
| Other Income | 3.13 | 11.21 | 17.41 | 25.59 | 19.97 | 22.74 | 25.21 | 24.87 | 14.44 | 16.54 |
| Operating Profit | 67.31 | 140.22 | 103.75 | 79.96 | 106.34 | 106.39 | 59.17 | 51.56 | 116.82 | 179.39 |
| Interest | 0.14 | 0.26 | 1.77 | 1.96 | 1.5 | 2.21 | 2.26 | 2.17 | 2.15 | 2.29 |
| Exceptional Items | -58.04 | -32.85 | ||||||||
| PBDT | 9.13 | 139.96 | 101.98 | 78 | 104.84 | 104.18 | 56.91 | 49.39 | 81.82 | 177.1 |
| Depreciation | 1.93 | 2.04 | 3.3 | 4.79 | 3.93 | 4.55 | 4.12 | 4.03 | 10.72 | 23.41 |
| Profit Before Tax | 7.2 | 137.92 | 98.68 | 73.21 | 100.91 | 99.63 | 52.79 | 45.36 | 71.1 | 153.69 |
| Tax | 3.51 | 33.81 | 20.83 | 17.18 | 26.12 | 24.91 | 13.16 | 9.87 | 17.81 | 39.1 |
| Profit After Tax | 3.69 | 104.11 | 77.85 | 56.03 | 74.79 | 74.72 | 39.63 | 35.49 | 53.29 | 114.59 |
| Net Profit | 3.69 | 104.11 | 77.85 | 56.03 | 74.79 | 74.72 | 39.63 | 35.49 | 53.29 | 114.59 |
| Equity Capital | 130.99 | 130.99 | 130.99 | 130.99 | 130.99 | 130.99 | 131.44 | 132.19 | 132.29 | 132.42 |
| Face Value (IN RS) | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Calculated EPS | 0.14 | 3.97 | 2.97 | 2.14 | 2.85 | 2.85 | 1.51 | 1.34 | 2.01 | 4.33 |
| Diluted Eps After Extraordinary Items | 0.14 | 3.97 | 2.97 | 2.14 | 2.85 | 2.84 | 1.47 | 1.31 | 1.93 | 4.25 |
| Diluted Eps Before Extraordinary Items | 0.14 | 3.97 | 2.97 | 2.14 | 2.85 | 2.84 | 1.47 | 1.31 | 1.93 | 4.25 |
STANDALONE QUARTERLY RESULT FOR JAGSONPAL PHARMACEUTICALS LIMITED
| Date End | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| No of months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months |
| Net Sales | 605.97 | 605.26 | 601.4 | 554.51 | 601.53 | 578.29 | 472.34 | 434.86 | 614.39 | 746.92 |
| Total Income | 609.1 | 616.47 | 618.81 | 580.1 | 621.5 | 601.03 | 497.55 | 459.73 | 628.83 | 763.46 |
| Total Expenditure | 541.79 | 476.25 | 515.06 | 500.14 | 515.16 | 494.64 | 438.38 | 408.17 | 512.01 | 584.07 |
| Other Income | 3.13 | 11.21 | 17.41 | 25.59 | 19.97 | 22.74 | 25.21 | 24.87 | 14.44 | 16.54 |
| Operating Profit | 67.31 | 140.22 | 103.75 | 79.96 | 106.34 | 106.39 | 59.17 | 51.56 | 116.82 | 179.39 |
| Interest | 0.14 | 0.26 | 1.77 | 1.96 | 1.5 | 2.21 | 2.26 | 2.17 | 2.15 | 2.29 |
| Exceptional Items | -58.04 | -32.85 | ||||||||
| PBDT | 9.13 | 139.96 | 101.98 | 78 | 104.84 | 104.18 | 56.91 | 49.39 | 81.82 | 177.1 |
| Depreciation | 1.93 | 2.04 | 3.3 | 4.79 | 3.93 | 4.55 | 4.12 | 4.03 | 10.72 | 23.41 |
| Profit Before Tax | 7.2 | 137.92 | 98.68 | 73.21 | 100.91 | 99.63 | 52.79 | 45.36 | 71.1 | 153.69 |
| Tax | 3.51 | 33.81 | 20.83 | 17.18 | 26.12 | 24.91 | 13.16 | 9.87 | 17.81 | 39.1 |
| Profit After Tax | 3.69 | 104.11 | 77.85 | 56.03 | 74.79 | 74.72 | 39.63 | 35.49 | 53.29 | 114.59 |
| Net Profit | 3.69 | 104.11 | 77.85 | 56.03 | 74.79 | 74.72 | 39.63 | 35.49 | 53.29 | 114.59 |
| Equity Capital | 130.99 | 130.99 | 130.99 | 130.99 | 130.99 | 130.99 | 131.44 | 132.19 | 132.29 | 132.42 |
| Face Value (IN RS) | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Calculated EPS | 0.14 | 3.97 | 2.97 | 2.14 | 2.85 | 2.85 | 1.51 | 1.34 | 2.01 | 4.33 |
| Diluted Eps After Extraordinary Items | 0.14 | 3.97 | 2.97 | 2.14 | 2.85 | 2.84 | 1.47 | 1.31 | 1.93 | 4.25 |
| Diluted Eps Before Extraordinary Items | 0.14 | 3.97 | 2.97 | 2.14 | 2.85 | 2.84 | 1.47 | 1.31 | 1.93 | 4.25 |
CONSOLIDATED ANNUAL RESULT FOR JAGSONPAL PHARMACEUTICALS LIMITED
| Date End | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|
| No of months | 12 months | 12 months | 12 months |
| Net Sales | 2260.97 | 2367.14 | 2087.02 |
| Total Income | 2294.33 | 2424.48 | 2179.81 |
| Total Expenditure | 2003.02 | 2025.63 | 1856.35 |
| Other Income | 33.36 | 57.34 | 92.79 |
| Operating Profit | 291.31 | 398.85 | 323.46 |
| Interest | 2.85 | 4.13 | 8.14 |
| Exceptional Items | -34.59 | ||
| PBDT | 288.46 | 360.13 | 315.32 |
| Depreciation | 15.26 | 12.05 | 16.63 |
| Profit Before Tax | 273.2 | 348.08 | 298.69 |
| Tax | 77.32 | 80.87 | 74.06 |
| Profit After Tax | 195.88 | 267.21 | 224.63 |
| Net Profit | 195.88 | 267.21 | 224.63 |
| Equity Capital | 130.99 | 130.99 | 132.19 |
| Face Value (IN RS) | 5 | 5 | 5 |
| Reserves | 1457.91 | 1741.83 | |
| Calculated EPS | 7.48 | 10.2 | 8.5 |
| Diluted Eps After Extraordinary Items | 7.48 | 10.2 | 8.46 |
| Diluted Eps Before Extraordinary Items | 7.48 | 10.2 | 8.46 |
STANDALONE ANNUAL RESULT FOR JAGSONPAL PHARMACEUTICALS LIMITED
| Date End | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|
| No of months | 12 months | 12 months | 12 months |
| Net Sales | 2260.97 | 2367.14 | 2087.02 |
| Total Income | 2294.33 | 2424.48 | 2179.81 |
| Total Expenditure | 2003.02 | 2025.63 | 1856.35 |
| Other Income | 33.36 | 57.34 | 92.79 |
| Operating Profit | 291.31 | 398.85 | 323.46 |
| Interest | 2.85 | 4.13 | 8.14 |
| Exceptional Items | -34.59 | ||
| PBDT | 288.46 | 360.13 | 315.32 |
| Depreciation | 15.26 | 12.05 | 16.63 |
| Profit Before Tax | 273.2 | 348.08 | 298.69 |
| Tax | 77.32 | 80.87 | 74.06 |
| Profit After Tax | 195.88 | 267.21 | 224.63 |
| Net Profit | 195.88 | 267.21 | 224.63 |
| Equity Capital | 130.99 | 130.99 | 132.19 |
| Face Value (IN RS) | 5 | 5 | 5 |
| Reserves | 1457.91 | 1741.83 | |
| Calculated EPS | 7.48 | 10.2 | 8.5 |
| Diluted Eps After Extraordinary Items | 7.48 | 10.2 | 8.46 |
| Diluted Eps Before Extraordinary Items | 7.48 | 10.2 | 8.46 |
CONSOLIDATED PROFIT / LOSS FOR JAGSONPAL PHARMACEUTICALS LIMITED
| YEAR | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| No of Months | 12 months | 12 months | 12 months | 12 months |
| Gross Sales | 187.95 Cr | 226.1 Cr | 257.16 Cr | 224.37 Cr |
| Sales | 187.88 Cr | 226.1 Cr | 257.16 Cr | 224.37 Cr |
| Net Sales | 187.95 Cr | 226.1 Cr | 236.71 Cr | 208.7 Cr |
| Increase/Decrease in Stock | 5.28 Cr | 5.61 Cr | 4.3 Cr | 3.9 Cr |
| Raw Material Consumed | 75.5 Cr | 90.17 Cr | 88.8 Cr | 76.08 Cr |
| Opening Raw Materials | 1.26 Cr | 6.94 Cr | 12.56 Cr | 7.81 Cr |
| Purchases Raw Materials | 44.31 Cr | 46.04 Cr | 26.46 Cr | 20.32 Cr |
| Closing Raw Materials | 6.94 Cr | 12.56 Cr | 7.81 Cr | 6.02 Cr |
| Other Direct Purchases / Brought in cost | 36.86 Cr | 49.75 Cr | 57.59 Cr | 53.98 Cr |
| Power & Fuel Cost | 52.3 Lk | 46.77 Lk | 28.8 Lk | 17.3 Lk |
| Electricity & Power | 52.3 Lk | 46.77 Lk | 28.8 Lk | 17.3 Lk |
| Employee Cost | 53.98 Cr | 57.68 Cr | 65.18 Cr | 61.8 Cr |
| Salaries, Wages & Bonus | 50.07 Cr | 52.93 Cr | 53.73 Cr | 45.55 Cr |
| Contributions to EPF & Pension Funds | 2.79 Cr | 2.84 Cr | 2.5 Cr | 2.86 Cr |
| Workmen and Staff Welfare Expenses | 14.47 Lk | 54.19 Lk | 18.3 Lk | 8 Lk |
| Other Manufacturing Expenses | 61.9 Lk | 1.05 Cr | 52 Lk | 72.7 Lk |
| Repairs and Maintenance | 46.11 Lk | 72.92 Lk | 35.2 Lk | 57.1 Lk |
| General and Administration Expenses | 18.75 Cr | 28.56 Cr | 22.29 Cr | 21.93 Cr |
| Rent , Rates & Taxes | 3.3 Cr | 3.32 Cr | 2.42 Cr | 1.46 Cr |
| Insurance | 76.18 Lk | 76.21 Lk | 1.04 Cr | 61.8 Lk |
| Printing and stationery | 28.87 Lk | 17.33 Lk | 7 Lk | 1.4 Lk |
| Professional and legal fees | 2.89 Cr | 8.69 Cr | 4.04 Cr | 2.64 Cr |
| Traveling and conveyance | 11.03 Cr | 14.8 Cr | 14.04 Cr | 16.36 Cr |
| Selling and Distribution Expenses | 12.99 Cr | 15.32 Cr | 18.61 Cr | 19.16 Cr |
| Advertisement & Sales Promotion | 11.83 Cr | 12.09 Cr | 15.46 Cr | 13.86 Cr |
| Sales Commissions & Incentives | 0 | 0 | 0 | 2.83 Cr |
| Freight and Forwarding | 1.16 Cr | 3.23 Cr | 3.14 Cr | 2.48 Cr |
| Miscellaneous Expenses | 1.22 Cr | 1.45 Cr | 2.57 Cr | 1.86 Cr |
| Provision for doubtful debts | 43.48 Lk | 4.21 Lk | 26.2 Lk | 76.7 Lk |
| Total Expenditure | 168.87 Cr | 200.3 Cr | 202.56 Cr | 185.64 Cr |
| Other Income | 4.39 Cr | 3.34 Cr | 5.73 Cr | 9.28 Cr |
| Interest Received | 2.99 Cr | 1.55 Cr | 3.43 Cr | 8.59 Cr |
| Profit on sale of Fixed Assets | 0 | 8.51 Lk | 35.9 Lk | 0 |
| Profits on sale of Investments | 0 | 0 | 59.2 Lk | 0 |
| Provision Written Back | 79.39 Lk | 48.68 Lk | 24.2 Lk | 6 Lk |
| Operating Profit | 23.47 Cr | 29.13 Cr | 39.88 Cr | 32.35 Cr |
| Interest | 51.35 Lk | 28.51 Lk | 41.3 Lk | 81.4 Lk |
| Interest on Term Loan | 42.75 Lk | 26.08 Lk | 0 | 0 |
| Bank Charges etc | 8.6 Lk | 2.43 Lk | 13.5 Lk | 3.7 Lk |
| PBDT | 22.96 Cr | 28.85 Cr | 39.47 Cr | 31.53 Cr |
| Depreciation | 1.09 Cr | 1.53 Cr | 1.2 Cr | 1.66 Cr |
| Profit Before Taxation & Exceptional Items | 21.87 Cr | 27.32 Cr | 38.27 Cr | 29.87 Cr |
| Exceptional Income / Expenses | 0 | 0 | -3.46 Cr | 0 |
| Profit Before Tax | 21.87 Cr | 27.32 Cr | 34.81 Cr | 29.87 Cr |
| Provision for Tax | 4.81 Cr | 7.73 Cr | 8.09 Cr | 7.41 Cr |
| Current Income Tax | 6.05 Cr | 7.4 Cr | 8.14 Cr | 7.56 Cr |
| Deferred Tax | -1.23 Cr | 32.88 Lk | 45.5 Lk | -15.4 Lk |
| Profit After Tax | 17.06 Cr | 19.59 Cr | 26.72 Cr | 22.46 Cr |
| Consolidated Net Profit | 17.06 Cr | 19.59 Cr | 26.72 Cr | 22.46 Cr |
| Profit Balance B/F | 47.69 Cr | 58.59 Cr | 69.37 Cr | 94.54 Cr |
| Appropriations | 64.75 Cr | 78.18 Cr | 96.09 Cr | 117 Cr |
| Other Appropriation | 6.16 Cr | 10.66 Cr | 1.56 Cr | 12.81 Cr |
| Equity Dividend % | 20 | 80 | 100 | 100 |
| Earnings Per Share | 6.51 | 7.48 | 10.2 | 8.5 |
| Adjusted EPS | 6.51 | 7.48 | 10.2 | 8.5 |
STANDALONE PROFIT / LOSS FOR JAGSONPAL PHARMACEUTICALS LIMITED
| YEAR | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| No of Months | 12 months | 12 months | 12 months | 12 months |
| Gross Sales | 187.95 Cr | 226.1 Cr | 257.16 Cr | 224.37 Cr |
| Sales | 187.88 Cr | 226.1 Cr | 257.16 Cr | 224.37 Cr |
| Net Sales | 187.95 Cr | 226.1 Cr | 236.71 Cr | 208.7 Cr |
| Increase/Decrease in Stock | 5.28 Cr | 5.61 Cr | 4.3 Cr | 3.9 Cr |
| Raw Material Consumed | 75.5 Cr | 90.17 Cr | 88.8 Cr | 76.08 Cr |
| Opening Raw Materials | 1.26 Cr | 6.94 Cr | 12.56 Cr | 7.81 Cr |
| Purchases Raw Materials | 44.31 Cr | 46.04 Cr | 26.46 Cr | 20.32 Cr |
| Closing Raw Materials | 6.94 Cr | 12.56 Cr | 7.81 Cr | 6.02 Cr |
| Other Direct Purchases / Brought in cost | 36.86 Cr | 49.75 Cr | 57.59 Cr | 53.98 Cr |
| Power & Fuel Cost | 52.3 Lk | 46.77 Lk | 28.8 Lk | 17.3 Lk |
| Electricity & Power | 52.3 Lk | 46.77 Lk | 28.8 Lk | 17.3 Lk |
| Employee Cost | 53.98 Cr | 57.68 Cr | 65.18 Cr | 61.8 Cr |
| Salaries, Wages & Bonus | 50.07 Cr | 52.93 Cr | 53.73 Cr | 45.55 Cr |
| Contributions to EPF & Pension Funds | 2.79 Cr | 2.84 Cr | 2.5 Cr | 2.86 Cr |
| Workmen and Staff Welfare Expenses | 14.47 Lk | 54.19 Lk | 18.3 Lk | 8 Lk |
| Other Manufacturing Expenses | 61.9 Lk | 1.05 Cr | 52 Lk | 72.7 Lk |
| Repairs and Maintenance | 46.11 Lk | 72.92 Lk | 35.2 Lk | 57.1 Lk |
| General and Administration Expenses | 18.75 Cr | 28.56 Cr | 22.29 Cr | 21.93 Cr |
| Rent , Rates & Taxes | 3.3 Cr | 3.32 Cr | 2.42 Cr | 1.46 Cr |
| Insurance | 76.18 Lk | 76.21 Lk | 1.04 Cr | 61.8 Lk |
| Printing and stationery | 28.87 Lk | 17.33 Lk | 7 Lk | 1.4 Lk |
| Professional and legal fees | 2.89 Cr | 8.69 Cr | 4.04 Cr | 2.64 Cr |
| Traveling and conveyance | 11.03 Cr | 14.8 Cr | 14.04 Cr | 16.36 Cr |
| Selling and Distribution Expenses | 12.99 Cr | 15.32 Cr | 18.61 Cr | 19.16 Cr |
| Advertisement & Sales Promotion | 11.83 Cr | 12.09 Cr | 15.46 Cr | 13.86 Cr |
| Sales Commissions & Incentives | 0 | 0 | 0 | 2.83 Cr |
| Freight and Forwarding | 1.16 Cr | 3.23 Cr | 3.14 Cr | 2.48 Cr |
| Miscellaneous Expenses | 1.22 Cr | 1.45 Cr | 2.57 Cr | 1.86 Cr |
| Provision for doubtful debts | 43.48 Lk | 4.21 Lk | 26.2 Lk | 76.7 Lk |
| Total Expenditure | 168.87 Cr | 200.3 Cr | 202.56 Cr | 185.64 Cr |
| Other Income | 4.39 Cr | 3.34 Cr | 5.73 Cr | 9.28 Cr |
| Interest Received | 2.99 Cr | 1.55 Cr | 3.43 Cr | 8.59 Cr |
| Profit on sale of Fixed Assets | 0 | 8.51 Lk | 35.9 Lk | 0 |
| Profits on sale of Investments | 0 | 0 | 59.2 Lk | 0 |
| Provision Written Back | 79.39 Lk | 48.68 Lk | 24.2 Lk | 6 Lk |
| Operating Profit | 23.47 Cr | 29.13 Cr | 39.88 Cr | 32.35 Cr |
| Interest | 51.35 Lk | 28.51 Lk | 41.3 Lk | 81.4 Lk |
| Interest on Term Loan | 42.75 Lk | 26.08 Lk | 0 | 0 |
| Bank Charges etc | 8.6 Lk | 2.43 Lk | 13.5 Lk | 3.7 Lk |
| PBDT | 22.96 Cr | 28.85 Cr | 39.47 Cr | 31.53 Cr |
| Depreciation | 1.09 Cr | 1.53 Cr | 1.2 Cr | 1.66 Cr |
| Profit Before Taxation & Exceptional Items | 21.87 Cr | 27.32 Cr | 38.27 Cr | 29.87 Cr |
| Exceptional Income / Expenses | 0 | 0 | -3.46 Cr | 0 |
| Profit Before Tax | 21.87 Cr | 27.32 Cr | 34.81 Cr | 29.87 Cr |
| Provision for Tax | 4.81 Cr | 7.73 Cr | 8.09 Cr | 7.41 Cr |
| Current Income Tax | 6.05 Cr | 7.4 Cr | 8.14 Cr | 7.56 Cr |
| Deferred Tax | -1.23 Cr | 32.88 Lk | 45.5 Lk | -15.4 Lk |
| Profit After Tax | 17.06 Cr | 19.59 Cr | 26.72 Cr | 22.46 Cr |
| Consolidated Net Profit | 17.06 Cr | 19.59 Cr | 26.72 Cr | 22.46 Cr |
| Profit Balance B/F | 47.69 Cr | 58.59 Cr | 69.37 Cr | 94.54 Cr |
| Appropriations | 64.75 Cr | 78.18 Cr | 96.09 Cr | 117 Cr |
| Other Appropriation | 6.16 Cr | 10.66 Cr | 1.56 Cr | 12.81 Cr |
| Equity Dividend % | 20 | 80 | 100 | 100 |
| Earnings Per Share | 6.51 | 7.48 | 10.2 | 8.5 |
| Adjusted EPS | 6.51 | 7.48 | 10.2 | 8.5 |
CONSOLIDATED CASH FLOW FOR JAGSONPAL PHARMACEUTICALS LIMITED
| Year End | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| No of Months | 12 months | 12 months | 12 months | 12 months |
| Profit Before Tax | 21.87 Cr | 27.32 Cr | 34.81 Cr | 29.87 Cr |
| Adjustment | -2.09 Cr | 2.91 Cr | 9.25 Cr | 8.27 Cr |
| Changes In working Capital | 11.59 Cr | -17.13 Cr | 9.88 Cr | 5.54 Cr |
| Cash Flow after changes in Working Capital | 31.37 Cr | 13.1 Cr | 53.93 Cr | 43.68 Cr |
| Cash Flow from Operating Activities | 28.22 Cr | 5.6 Cr | 46.66 Cr | 35.17 Cr |
| Cash Flow from Investing Activities | -2.26 Cr | -26.21 Cr | -57.67 Cr | -24.55 Cr |
| Cash Flow from Financing Activitie | -6.83 Cr | -12.3 Cr | -45.7 Lk | -8.91 Cr |
| Net Cash Inflow / Outflow | 19.13 Cr | -32.91 Cr | -11.47 Cr | 1.71 Cr |
| Opening Cash & Cash Equivalents | 39.81 Cr | 58.94 Cr | 22.53 Cr | 11.05 Cr |
| Closing Cash & Cash Equivalent | 58.94 Cr | 26.03 Cr | 11.05 Cr | 12.76 Cr |
STANDALONE CASH FLOW FOR JAGSONPAL PHARMACEUTICALS LIMITED
| Year End | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| No of Months | 12 months | 12 months | 12 months | 12 months |
| Profit Before Tax | 21.87 Cr | 27.32 Cr | 34.81 Cr | 29.87 Cr |
| Adjustment | -2.09 Cr | 2.91 Cr | 9.25 Cr | 8.27 Cr |
| Changes In working Capital | 11.59 Cr | -17.13 Cr | 9.88 Cr | 5.54 Cr |
| Cash Flow after changes in Working Capital | 31.37 Cr | 13.1 Cr | 53.93 Cr | 43.68 Cr |
| Cash Flow from Operating Activities | 28.22 Cr | 5.6 Cr | 46.66 Cr | 35.17 Cr |
| Cash Flow from Investing Activities | -2.26 Cr | -26.21 Cr | -57.67 Cr | -24.55 Cr |
| Cash Flow from Financing Activitie | -6.83 Cr | -12.3 Cr | -45.7 Lk | -8.91 Cr |
| Net Cash Inflow / Outflow | 19.13 Cr | -32.91 Cr | -11.47 Cr | 1.71 Cr |
| Opening Cash & Cash Equivalents | 39.81 Cr | 58.94 Cr | 22.53 Cr | 11.05 Cr |
| Closing Cash & Cash Equivalent | 58.94 Cr | 26.03 Cr | 11.05 Cr | 12.76 Cr |
CONSOLIDATED BALANCE SHEET FOR JAGSONPAL PHARMACEUTICALS LIMITED
| YEAR | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| Share Capital | 13.1 Cr | 13.1 Cr | 13.1 Cr | 13.22 Cr |
| Equity - Authorised | 15 Cr | 15 Cr | 15 Cr | 15 Cr |
| Equity - Issued | 13.1 Cr | 13.1 Cr | 13.1 Cr | 13.22 Cr |
| Equity Paid Up | 13.1 Cr | 13.1 Cr | 13.1 Cr | 13.22 Cr |
| Face Value | 5 | 5 | 5 | 5 |
| Total Reserves | 108.83 Cr | 117.76 Cr | 137.03 Cr | 157.11 Cr |
| Securities Premium | 60 Lk | 60 Lk | 60 Lk | 11.12 Cr |
| Profit & Loss Account Balance | 58.59 Cr | 67.52 Cr | 94.54 Cr | 104.19 Cr |
| General Reserves | 41.8 Cr | 41.8 Cr | 41.8 Cr | 41.8 Cr |
| Reserve excluding Revaluation Reserve | 100.99 Cr | 109.92 Cr | 137.03 Cr | 157.11 Cr |
| Revaluation reserve | 7.84 Cr | 7.84 Cr | 0 | 0 |
| Shareholder's Funds | 121.93 Cr | 130.86 Cr | 158.89 Cr | 187.4 Cr |
| Deferred Tax Assets / Liabilities | 1.86 Cr | 2.19 Cr | 2.16 Cr | 2.07 Cr |
| Deferred Tax Assets | 25.19 Lk | 0 | 4.1 Lk | 2.25 Cr |
| Deferred Tax Liability | 2.11 Cr | 2.19 Cr | 2.2 Cr | 4.32 Cr |
| Other Long Term Liabilities | 0 | 0 | 5.25 Cr | 7.56 Cr |
| Long Term Provisions | 1.8 Lk | 1.26 Cr | 1.08 Cr | 91.8 Lk |
| Total Non-Current Liabilities | 1.88 Cr | 3.44 Cr | 8.48 Cr | 10.55 Cr |
| Trade Payables | 18.05 Cr | 16.29 Cr | 16.36 Cr | 7.6 Cr |
| Sundry Creditors | 18.05 Cr | 16.29 Cr | 16.36 Cr | 7.6 Cr |
| Other Current Liabilities | 10.89 Cr | 9.42 Cr | 10.81 Cr | 10.78 Cr |
| Advances received from customers | 0 | 0 | 61.2 Lk | 1.29 Cr |
| Short Term Borrowings | 6.79 Cr | 0 | 0 | 0 |
| Short Term Provisions | 4.67 Cr | 8.45 Cr | 8.01 Cr | 9.26 Cr |
| Provision for Tax | 3.82 Cr | 7.96 Cr | 7.63 Cr | 8.51 Cr |
| Total Current Liabilities | 40.4 Cr | 34.16 Cr | 35.18 Cr | 27.64 Cr |
| Total Liabilities | 164.2 Cr | 168.46 Cr | 202.56 Cr | 225.59 Cr |
| Gross Block | 60.12 Cr | 60.28 Cr | 33.25 Cr | 11.59 Cr |
| Less: Accumulated Depreciation | 34.4 Cr | 35.53 Cr | 11.75 Cr | 2.28 Cr |
| Less: Impairment of Assets | 0 | 0 | -2.78 Cr | 0 |
| Net Block | 25.72 Cr | 24.75 Cr | 24.28 Cr | 9.3 Cr |
| Non Current Investments | 12.06 Cr | 20.58 Cr | 1.12 Cr | 0 |
| Long Term Investment | 12.06 Cr | 20.58 Cr | 1.12 Cr | 0 |
| Quoted | 5,000 | 5,000 | 10.3 Lk | 0 |
| Unquoted | 12.06 Cr | 20.58 Cr | 1.02 Cr | 0 |
| Long Term Loans & Advances | 5.66 Cr | 9.93 Cr | 69.3 Lk | 1.72 Cr |
| Other Non Current Assets | 28.61 Lk | 2.42 Cr | 4.3 Cr | 6.81 Cr |
| Total Non-Current Assets | 43.73 Cr | 57.68 Cr | 30.39 Cr | 17.82 Cr |
| Currents Investments | 3.25 Cr | 22.14 Cr | 0 | 0 |
| Quoted | 3.25 Cr | 22.14 Cr | 0 | 0 |
| Unquoted | 12.06 Cr | 20.58 Cr | 1.02 Cr | 0 |
| Inventories | 29.72 Cr | 29.74 Cr | 20.68 Cr | 15 Cr |
| Raw Materials | 6.94 Cr | 12.56 Cr | 7.81 Cr | 6.02 Cr |
| Work-in Progress | 10.31 Cr | 2.7 Cr | 1.08 Cr | 1.26 Cr |
| Finished Goods | 12.47 Cr | 14.47 Cr | 4.72 Cr | 3.8 Cr |
| Stores and Spare | 0 | 1.24 Lk | 0 | 0 |
| Sundry Debtors | 12.66 Cr | 15.58 Cr | 20.87 Cr | 10.95 Cr |
| Debtors more than Six months | 43.48 Lk | 68.95 Lk | 1.31 Cr | 1.38 Cr |
| Debtors Others | 12.66 Cr | 15.36 Cr | 20.16 Cr | 10.62 Cr |
| Cash and Bank | 60.23 Cr | 26.15 Cr | 114.63 Cr | 147.93 Cr |
| Cash in hand | 31.14 Lk | 89.4 Lk | 5.4 Lk | 0 |
| Balances at Bank | 59.92 Cr | 25.26 Cr | 114.57 Cr | 147.93 Cr |
| Other Current Assets | 27.31 Lk | 3.61 Cr | 1.15 Cr | 1.36 Cr |
| Prepaid Expenses | 0 | 3.61 Cr | 1.07 Cr | 1.36 Cr |
| Short Term Loans and Advances | 14.34 Cr | 13.55 Cr | 14.84 Cr | 15.35 Cr |
| Advances recoverable in cash or in kind | 8.05 Cr | 7.95 Cr | 4.2 Cr | 2.23 Cr |
| Advance income tax and TDS | 0 | 0 | 7.61 Cr | 8.51 Cr |
| Total Current Assets | 120.48 Cr | 110.78 Cr | 172.17 Cr | 190.59 Cr |
| Net Current Assets (Including Current Investments) | 80.08 Cr | 76.62 Cr | 136.99 Cr | 162.95 Cr |
| Total Assets | 164.2 Cr | 168.46 Cr | 202.56 Cr | 225.59 Cr |
| Contingent Liabilities | 5.99 Cr | 7.96 Cr | 6.09 Cr | 11.22 Cr |
| Total Debt | 6.79 Cr | 0 | 0 | 0 |
| Book Value | 0 | 46.96 | 57.3 | 64.43 |
| Adjusted Book Value | 43.55 | 46.96 | 57.3 | 64.43 |
STANDALONE BALANCE SHEET FOR JAGSONPAL PHARMACEUTICALS LIMITED
| YEAR | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| Share Capital | 13.1 Cr | 13.1 Cr | 13.1 Cr | 13.22 Cr |
| Equity - Authorised | 15 Cr | 15 Cr | 15 Cr | 15 Cr |
| Equity - Issued | 13.1 Cr | 13.1 Cr | 13.1 Cr | 13.22 Cr |
| Equity Paid Up | 13.1 Cr | 13.1 Cr | 13.1 Cr | 13.22 Cr |
| Face Value | 5 | 5 | 5 | 5 |
| Total Reserves | 108.83 Cr | 117.76 Cr | 137.03 Cr | 157.11 Cr |
| Securities Premium | 60 Lk | 60 Lk | 60 Lk | 11.12 Cr |
| Profit & Loss Account Balance | 58.59 Cr | 67.52 Cr | 94.54 Cr | 104.19 Cr |
| General Reserves | 41.8 Cr | 41.8 Cr | 41.8 Cr | 41.8 Cr |
| Reserve excluding Revaluation Reserve | 100.99 Cr | 109.92 Cr | 137.03 Cr | 157.11 Cr |
| Revaluation reserve | 7.84 Cr | 7.84 Cr | 0 | 0 |
| Shareholder's Funds | 121.93 Cr | 130.86 Cr | 158.89 Cr | 187.4 Cr |
| Deferred Tax Assets / Liabilities | 1.86 Cr | 2.19 Cr | 2.16 Cr | 2.07 Cr |
| Deferred Tax Assets | 25.19 Lk | 0 | 4.1 Lk | 2.25 Cr |
| Deferred Tax Liability | 2.11 Cr | 2.19 Cr | 2.2 Cr | 4.32 Cr |
| Other Long Term Liabilities | 0 | 0 | 5.25 Cr | 7.56 Cr |
| Long Term Provisions | 1.8 Lk | 1.26 Cr | 1.08 Cr | 91.8 Lk |
| Total Non-Current Liabilities | 1.88 Cr | 3.44 Cr | 8.48 Cr | 10.55 Cr |
| Trade Payables | 18.05 Cr | 16.29 Cr | 16.36 Cr | 7.6 Cr |
| Sundry Creditors | 18.05 Cr | 16.29 Cr | 16.36 Cr | 7.6 Cr |
| Other Current Liabilities | 10.89 Cr | 9.42 Cr | 10.81 Cr | 10.78 Cr |
| Advances received from customers | 0 | 0 | 61.2 Lk | 1.29 Cr |
| Short Term Borrowings | 6.79 Cr | 0 | 0 | 0 |
| Short Term Provisions | 4.67 Cr | 8.45 Cr | 8.01 Cr | 9.26 Cr |
| Provision for Tax | 3.82 Cr | 7.96 Cr | 7.63 Cr | 8.51 Cr |
| Total Current Liabilities | 40.4 Cr | 34.16 Cr | 35.18 Cr | 27.64 Cr |
| Total Liabilities | 164.2 Cr | 168.46 Cr | 202.56 Cr | 225.59 Cr |
| Gross Block | 60.12 Cr | 60.28 Cr | 33.25 Cr | 11.59 Cr |
| Less: Accumulated Depreciation | 34.4 Cr | 35.53 Cr | 11.75 Cr | 2.28 Cr |
| Less: Impairment of Assets | 0 | 0 | -2.78 Cr | 0 |
| Net Block | 25.72 Cr | 24.75 Cr | 24.28 Cr | 9.3 Cr |
| Non Current Investments | 12.06 Cr | 20.58 Cr | 1.12 Cr | 0 |
| Long Term Investment | 12.06 Cr | 20.58 Cr | 1.12 Cr | 0 |
| Quoted | 5,000 | 5,000 | 10.3 Lk | 0 |
| Unquoted | 12.06 Cr | 20.58 Cr | 1.02 Cr | 0 |
| Long Term Loans & Advances | 5.66 Cr | 9.93 Cr | 69.3 Lk | 1.72 Cr |
| Other Non Current Assets | 28.61 Lk | 2.42 Cr | 4.3 Cr | 6.81 Cr |
| Total Non-Current Assets | 43.73 Cr | 57.68 Cr | 30.39 Cr | 17.82 Cr |
| Currents Investments | 3.25 Cr | 22.14 Cr | 0 | 0 |
| Quoted | 3.25 Cr | 22.14 Cr | 0 | 0 |
| Unquoted | 12.06 Cr | 20.58 Cr | 1.02 Cr | 0 |
| Inventories | 29.72 Cr | 29.74 Cr | 20.68 Cr | 15 Cr |
| Raw Materials | 6.94 Cr | 12.56 Cr | 7.81 Cr | 6.02 Cr |
| Work-in Progress | 10.31 Cr | 2.7 Cr | 1.08 Cr | 1.26 Cr |
| Finished Goods | 12.47 Cr | 14.47 Cr | 4.72 Cr | 3.8 Cr |
| Stores and Spare | 0 | 1.24 Lk | 0 | 0 |
| Sundry Debtors | 12.66 Cr | 15.58 Cr | 20.87 Cr | 10.95 Cr |
| Debtors more than Six months | 43.48 Lk | 68.95 Lk | 1.31 Cr | 1.38 Cr |
| Debtors Others | 12.66 Cr | 15.36 Cr | 20.16 Cr | 10.62 Cr |
| Cash and Bank | 60.23 Cr | 26.15 Cr | 114.63 Cr | 147.93 Cr |
| Cash in hand | 31.14 Lk | 89.4 Lk | 5.4 Lk | 0 |
| Balances at Bank | 59.92 Cr | 25.26 Cr | 114.57 Cr | 147.93 Cr |
| Other Current Assets | 27.31 Lk | 3.61 Cr | 1.15 Cr | 1.36 Cr |
| Prepaid Expenses | 0 | 3.61 Cr | 1.07 Cr | 1.36 Cr |
| Short Term Loans and Advances | 14.34 Cr | 13.55 Cr | 14.84 Cr | 15.35 Cr |
| Advances recoverable in cash or in kind | 8.05 Cr | 7.95 Cr | 4.2 Cr | 2.23 Cr |
| Advance income tax and TDS | 0 | 0 | 7.61 Cr | 8.51 Cr |
| Total Current Assets | 120.48 Cr | 110.78 Cr | 172.17 Cr | 190.59 Cr |
| Net Current Assets (Including Current Investments) | 80.08 Cr | 76.62 Cr | 136.99 Cr | 162.95 Cr |
| Total Assets | 164.2 Cr | 168.46 Cr | 202.56 Cr | 225.59 Cr |
| Contingent Liabilities | 5.99 Cr | 7.96 Cr | 6.09 Cr | 11.22 Cr |
| Total Debt | 6.79 Cr | 0 | 0 | 0 |
| Book Value | 0 | 46.96 | 57.3 | 64.43 |
| Adjusted Book Value | 43.55 | 46.96 | 57.3 | 64.43 |
FINANCIAL RATIOS (CONSOLIDATED) FOR JAGSONPAL PHARMACEUTICALS LIMITED
| YEAR | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| Operational & Financial Ratios | ||||
| Earnings Per Share (Rs) | 6.51 | 7.48 | 10.2 | 8.5 |
| CEPS(Rs) | 6.93 | 8.06 | 10.66 | 9.13 |
| DPS(Rs) | 1 | 4 | 5 | 5 |
| Book NAV/Share(Rs) | 43.55 | 46.96 | 57.3 | 64.43 |
| Tax Rate(%) | 22.01 | 28.3 | 23.23 | 24.79 |
| Margin Ratios | ||||
| Core EBITDA Margin(%) | 10.15 | 11.41 | 13.28 | 10.28 |
| EBIT Margin(%) | 11.91 | 12.21 | 13.7 | 13.68 |
| Pre Tax Margin(%) | 11.64 | 12.08 | 13.54 | 13.31 |
| PAT Margin (%) | 9.08 | 8.66 | 10.39 | 10.01 |
| Cash Profit Margin (%) | 9.65 | 9.34 | 10.86 | 10.75 |
| Performance Ratios | ||||
| ROA(%) | 10.9 | 11.78 | 14.29 | 10.49 |
| ROE(%) | 15.7 | 16.52 | 18.89 | 14.02 |
| ROCE(%) | 19.43 | 22.64 | 24.15 | 17.72 |
| Asset Turnover(x) | 1.2 | 1.36 | 1.38 | 1.05 |
| Sales/Fixed Asset(x) | 3.18 | 3.76 | 5.63 | 10.09 |
| Working Capital/Sales(x) | 2.35 | 2.95 | 1.88 | 1.38 |
| Efficiency Ratios | ||||
| Fixed Capital/Sales(x) | 0.31 | 0.27 | 0.18 | 0.1 |
| Receivable days | 33.13 | 22.8 | 25.87 | 25.88 |
| Inventory Days | 57.34 | 48 | 35.78 | 29.02 |
| Payable days | 38.49 | 65.42 | 68.44 | 55.17 |
| Valuation Parameters | ||||
| PER(x) | 12.22 | 41.94 | 28.42 | 32.94 |
| PCE(x) | 11.49 | 38.91 | 27.2 | 30.67 |
| Price/Book(x) | 1.83 | 6.68 | 5.06 | 4.34 |
| Yield(%) | 1.26 | 1.28 | 1.72 | 1.79 |
| EV/Net Sales(x) | 0.82 | 3.52 | 2.72 | 2.84 |
| EV/Core EBITDA(x) | 6.6 | 27.31 | 16.17 | 18.3 |
| EV/EBIT(x) | 6.92 | 28.82 | 18.31 | 19.29 |
| EV/CE(x) | 0.94 | 4.72 | 3.18 | 3.16 |
| M Cap / Sales | 1.11 | 3.63 | 3.21 | 3.55 |
| Growth Ratio | ||||
| Net Sales Growth(%) | 18.53 | 20.3 | 8.79 | -11.83 |
| Core EBITDA Growth(%) | 112.25 | 24.11 | 40.18 | -18.9 |
| EBIT Growth(%) | 125.46 | 23.31 | 30.8 | -12.89 |
| PAT Growth(%) | 116.73 | 14.82 | 41.72 | -15.94 |
| EPS Growth(%) | 116.73 | 14.82 | 41.72 | -16.7 |
| Financial Stability Ratios | ||||
| Total Debt/Equity(x) | 0.06 | 0 | 0 | 0 |
| Current Ratio(x) | 2.98 | 3.24 | 4.89 | 6.9 |
| Quick Ratio(x) | 2.25 | 2.37 | 4.31 | 6.35 |
| Interest Cover(x) | 43.59 | 96.82 | 85.28 | 37.69 |
| Total Debt/Mcap(x) | 0.03 | 0 | 0 | 0 |
FINANCIAL RATIOS (STANDALONE) FOR JAGSONPAL PHARMACEUTICALS LIMITED
| YEAR | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| Operational & Financial Ratios | ||||
| Earnings Per Share (Rs) | 6.51 | 7.48 | 10.2 | 8.5 |
| CEPS(Rs) | 6.93 | 8.06 | 10.66 | 9.13 |
| DPS(Rs) | 1 | 4 | 5 | 5 |
| Book NAV/Share(Rs) | 43.55 | 46.96 | 57.3 | 64.43 |
| Tax Rate(%) | 22.01 | 28.3 | 23.23 | 24.79 |
| Margin Ratios | ||||
| Core EBITDA Margin(%) | 10.15 | 11.41 | 13.28 | 10.28 |
| EBIT Margin(%) | 11.91 | 12.21 | 13.7 | 13.68 |
| Pre Tax Margin(%) | 11.64 | 12.08 | 13.54 | 13.31 |
| PAT Margin (%) | 9.08 | 8.66 | 10.39 | 10.01 |
| Cash Profit Margin (%) | 9.65 | 9.34 | 10.86 | 10.75 |
| Performance Ratios | ||||
| ROA(%) | 10.9 | 11.78 | 14.29 | 10.49 |
| ROE(%) | 15.7 | 16.52 | 18.89 | 14.02 |
| ROCE(%) | 19.43 | 22.64 | 24.15 | 17.72 |
| Asset Turnover(x) | 1.2 | 1.36 | 1.38 | 1.05 |
| Sales/Fixed Asset(x) | 3.18 | 3.76 | 5.63 | 10.09 |
| Working Capital/Sales(x) | 2.35 | 2.95 | 1.88 | 1.38 |
| Efficiency Ratios | ||||
| Fixed Capital/Sales(x) | 0.31 | 0.27 | 0.18 | 0.1 |
| Receivable days | 33.13 | 22.8 | 25.87 | 25.88 |
| Inventory Days | 57.34 | 48 | 35.78 | 29.02 |
| Payable days | 38.49 | 65.42 | 68.44 | 55.17 |
| Valuation Parameters | ||||
| PER(x) | 12.22 | 41.94 | 28.42 | 32.94 |
| PCE(x) | 11.49 | 38.91 | 27.2 | 30.67 |
| Price/Book(x) | 1.83 | 6.68 | 5.06 | 4.34 |
| Yield(%) | 1.26 | 1.28 | 1.72 | 1.79 |
| EV/Net Sales(x) | 0.82 | 3.52 | 2.72 | 2.84 |
| EV/Core EBITDA(x) | 6.6 | 27.31 | 16.17 | 18.3 |
| EV/EBIT(x) | 6.92 | 28.82 | 18.31 | 19.29 |
| EV/CE(x) | 0.94 | 4.72 | 3.18 | 3.16 |
| M Cap / Sales | 1.11 | 3.63 | 3.21 | 3.55 |
| Growth Ratio | ||||
| Net Sales Growth(%) | 18.53 | 20.3 | 8.79 | -11.83 |
| Core EBITDA Growth(%) | 112.25 | 24.11 | 40.18 | -18.9 |
| EBIT Growth(%) | 125.46 | 23.31 | 30.8 | -12.89 |
| PAT Growth(%) | 116.73 | 14.82 | 41.72 | -15.94 |
| EPS Growth(%) | 116.73 | 14.82 | 41.72 | -16.7 |
| Financial Stability Ratios | ||||
| Total Debt/Equity(x) | 0.06 | 0 | 0 | 0 |
| Current Ratio(x) | 2.98 | 3.24 | 4.89 | 6.9 |
| Quick Ratio(x) | 2.25 | 2.37 | 4.31 | 6.35 |
| Interest Cover(x) | 43.59 | 96.82 | 85.28 | 37.69 |
| Total Debt/Mcap(x) | 0.03 | 0 | 0 | 0 |
SHARE HOLDING PATTERN FOR JAGSONPAL PHARMACEUTICALS LIMITED
| Date | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoters % | 68.71 | 68.71 | 68.71 | 24.99 | 24.99 | 24.99 | 24.90 | 24.76 | 24.74 | 24.72 |
| FII % | 0.00 | 0.00 | 0.00 | 0.00 | 0.37 | 0.38 | 0.53 | 0.73 | 1.10 | 2.30 |
| DII % | 0.54 | 0.28 | 0.77 | 0.82 | 0.82 | 0.82 | 0.82 | 0.84 | 0.85 | 0.00 |
| Public % | 30.61 | 30.87 | 30.41 | 30.36 | 30.08 | 30.08 | 30.17 | 30.33 | 30.01 | 29.62 |
PEER COMPARISON FOR JAGSONPAL PHARMACEUTICALS LIMITED
CORPORATE ACTIONS FOR JAGSONPAL PHARMACEUTICALS
| Exchange Date | Purpose | Book Closure Dates |
|---|---|---|
| BSE 16-Oct-2024 | Board Meeting - Stock Split & Quarterly Results | 23-Oct-2024 |
| BSE 16-Oct-2024 | Split or Consolidation - Stock Split & Quarterly Results | |
| BSE 31-Jul-2024 | Board Meeting - Quarterly Results | 07-Aug-2024 |
| BSE 21-May-2024 | Dividend - Rs.5.0000 per share(100%)Final Dividend | |
| BSE 13-May-2024 | Board Meeting - Final Dividend & Audited Results | 20-May-2024 |
| BSE 25-Jan-2024 | Board Meeting - Quarterly Results | 02-Feb-2024 |
| BSE 26-Oct-2023 | Board Meeting - Quarterly Results | 03-Nov-2023 |
| BSE 25-Jul-2023 | Board Meeting - Quarterly Results | 02-Aug-2023 |
| BSE 23-May-2023 | Dividend - Rs.5.0000 per share(100%)Dividend | |
| BSE 15-May-2023 | Board Meeting - Dividend & Audited Results | 23-May-2023 |
| BSE 31-Jan-2023 | Board Meeting - Quarterly Results | 08-Feb-2023 |
| BSE 03-Nov-2022 | Board Meeting - Quarterly Results | 09-Nov-2022 |
| BSE 04-Aug-2022 | Board Meeting - Quarterly Results | 09-Aug-2022 |
| BSE 23-May-2022 | Board Meeting - Audited Results & Quarterly Results | 30-May-2022 |
| BSE 20-May-2022 | Book Closure - E.G.M. | 10-Jun-2022 17-Jun-2022 |
| BSE 04-May-2022 | Board Meeting - Inter alia, to consider and approve the alteration in AOA and other routine matters. | 13-May-2022 |
| BSE 03-Feb-2022 | Board Meeting - Quarterly Results | 11-Feb-2022 |
| BSE 19-Jan-2022 | Board Meeting - JAGSONPAL PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/01/2022 ,inter alia, to consider and approve unaudited financial results for the quarter and nine months ended 31.December.2021. | 27-Jan-2022 |
| BSE 19-Oct-2021 | Dividend - Rs.4.0000 per share(80%)Interim Dividend | |
| BSE 12-Oct-2021 | Board Meeting - Quarterly Results & Interim Dividend | 19-Oct-2021 |
| BSE 13-Sep-2021 | Book Closure - A.G.M. & Rs.1.0000 per share(20%)Dividend | 24-Sep-2021 30-Sep-2021 |
| BSE 07-Sep-2021 | AGM - A.G.M. & Rs.1.0000 per share(20%)Dividend | 30-Sep-2021 30-Sep-2021 |
CORPORATE ANNOUNCEMENTS FOR JAGSONPAL PHARMACEUTICALS
| Exchange Date | Category File | Description |
|---|---|---|
| BSE 29-Oct-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Earnings Call Transcript Please find enclosed Transcript for the Jagsonpal Pharmaceuticals Limited Q2FY25 Earning Confrence Call held on October 24 2024 at 11:00 AM for discussion of Q2FY25 & H1FY25 Financial Results. |
| BSE 25-Oct-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Newspaper Publication Pursuant to the provision of Regulation 47 of SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 please find enclosed copies of advertisement publisher on October 25 2024 in Business Standard (English) and Business Standard (Hindi) newspaper. |
| BSE 24-Oct-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome Audio Recording of Jagsonpal Pharmaceuticals Limited Q2 FY25 and H1 FY25 Earnings Conference Call on October 24 2024 |
| BSE 24-Oct-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Investor Presentation In continuation to earlier intimation dated October 23 2024 Please find enclosed herewith revised investor presentation for quarter and half year ended September 30 2024 due to inadvertent error in slide 20 and then same has been rectificed. |
| BSE 23-Oct-2024 | General Announcements FILE | Related Party Transaction For The Half Year Ended September 30 2024 Please find enclosed related party transaction for half year ended September 30 2024 |
| BSE 23-Oct-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association Please note that pursunat to split of shares there is change in authorised share capital clause of MOA and AOA |
| BSE 23-Oct-2024 | Intimation FILE | Corporate Action-Intimation of Sub division / Stock Split Please find enclosed intimation for split of shares from face value of Rs. 5 to Rs.2 |
| BSE 23-Oct-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Press Release / Media Release Please find enclosed press release and investor presentation for quarter and half year ended September 30 2024. |
| BSE 23-Oct-2024 | Outcome FILE | Outcome Of Board Meeting Held On October 23 2024 & Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements Regulations 2015 Please find enclosed Unaudited financial result and limited review report for quarter and half year ended September 30 2024 |
| BSE 23-Oct-2024 | Outcome FILE | Board Meeting Outcome for Outcome Of Board Meeting Held On October 23 2024 & Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements Regulations 2015 Pursuant to Regulation 30 (read with Part A of Schedule III) and Regulation 33 of the Securities andExchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015(SEBI Listing Regulations) we would like to inform you that the Board of Directors at its Meetingheld today inter-alia considered and approved the following:1. Unaudited Financial Results along with Limited Review Report issued by the StatutoryAuditors of the Company for the quarter and half year ended September 30 2024.2. Sub-division/ split of the existing Equity Shares of the Company such that each Equity Sharehaving face value of Rs. 5/- (Rupees Five only) each fully paid-up be sub-divided/split intosuch number of Equity Shares having face value of Rs. 2 each fully paid-up subject to theapproval of Equity Shareholders of the Company through Postal Ballot. |
| BSE 16-Oct-2024 | General Announcements FILE | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 In Compliance with Regulation 74(5) of SEBI ( Depositories and Participants) Regulations 2018 we are enclosing herewith a copy of the certificate received from M/s MCS Share Transfer Agent Limited the Registrar and Share Transfer Agent of the company for the quarter ended September 30 2024. |
| BSE 16-Oct-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform you that the Company as a part of its investors engagement activities has scheduled a conference call with the Analysts / Investors on Thursday October 24 2024 to discuss its Q2 FY25 & H1 FY25 financial results. |
| BSE 16-Oct-2024 | Intimation FILE | Board Meeting Intimation for Consider And Approve Unaudited Financial Results Of The Company For The Quarter And Half Year Ended September 30 2024. JAGSONPAL PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/10/2024 inter alia to consider and approve (i) Unaudited Financial Results of the Company for the quarter and half year ended September 30 2024.(ii) Proposal for sub-division/split of existing Equity Shares of the Company having a face value of Rs. 5/- each fully paid up in such manner as may be determined by the Board of Directors subject to the approval of Equity Shareholders of the Company and other applicable approval(s) (if any). |
| BSE 14-Oct-2024 | General FILE | Disclosures under Reg. 10(7) of SEBI (SAST) Regulations 2011 The Exchange has received the disclosure under Regulation 10(7) in respect of acquisition under Regulation 10(1)(a)(iii)of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Infinity Portfolio Holdings |
| BSE 12-Oct-2024 | General Announcements FILE | Announcement Under Regulation 30 - Receipt Of Settlement Order Please find enclosed intimation for receipt of Settlement Order from the Securities and Exchange Board of India in respect of settlement application filed by Mr. Rajpal Singh Kochhar one of the Promoters of the Company. |
| BSE 27-Sep-2024 | Intimation FILE | Closure of Trading Window In terms of SEBI (Prohibition of Insider Trading) Regulations 2015 and Companys Code of Conduct to regulate monitor and report trading by designated persons & their immediate relatives the Trading Window for dealing in securities of the Company shall remain closed with effect from Tuesday October 01 2024 till the end of 48 hours after declaration of Unaudited Financial Results for the quarter and half year ended September 30 2024. |
| BSE 26-Sep-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS Pursuant to SEBI (LODR) Reg. 2015 as amended we are pleased to inform you that Nomination and Remuneration Committee has issued and alloted 27 500 equity shares of Rs. 5 Each to eligible employee of the Company upon excercise of vested options. |
| BSE 19-Sep-2024 | Outcome FILE | Shareholder Meeting / Postal Ballot-Scrutinizer''s Report Please find enclosed herewith Voting results and Scrunitizer results of 45th Annual General meeting held on September 18 2024 at 03:30 p.m. |
| BSE 18-Sep-2024 | Outcome FILE | Shareholder Meeting / Postal Ballot-Outcome of AGM Pursuant to Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 Please find enclosed herewith summary of Proceedings of the 45th AGM of the Company held on Wednesday September 18 2024 at 3:30 P.M. (IST) through Video Conference/Other Audio-Visual Means. The detailed results of e-voting (both for remote e-voting and Voting at AGM) along with Scrutinizer report shall be intimated separately. |
| BSE 18-Sep-2024 | General Announcements FILE | Disclosure As Per Regulation 7(1) Of SEBI (Prohibition Of Insider Trading) Regulations 2015 Please find enclosed herewith disclosure under Regulation 7(1) of SEBI (Prohibition of Insider Trading) Regulations 2015 |
| BSE 18-Sep-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Please find enclosed the schedule of Analysts/Institutional Investors Meeting. |
| BSE 18-Sep-2024 | General FILE | Disclosures under Reg. 10(6) of SEBI (SAST) Regulations 2011 The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Infinity Portfolio Holdings |
| BSE 18-Sep-2024 | General FILE | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Infinity Holdings & Others |
| BSE 18-Sep-2024 | General FILE | Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011 The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Infinity Portfolio Holdings & PACs |
| BSE 06-Sep-2024 | General FILE | Disclosures under Reg. 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (SAST) Regulations 2011 The Exchange has received the disclosure under Regulation 10(5) in respect of acquisition under Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Infinity Portfolio Holdings |
| BSE 03-Sep-2024 | General Announcements FILE | Appointment Of Investor Relation Agency we would like to inform the exchange that Company has appointed M/s. Go India Advisors LLP as its Investor Relationship Agency for providing Investor Relation Advisory services to the Company. |
| BSE 28-Aug-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Newspaper Publication In terms of regulation 30 of the SEBI (LODR) Regulations 2015 please find enclosed copies of newspaper publication post dispatch of annual report. |
| BSE 27-Aug-2024 | General Announcements FILE | Notice Of 45Th Annual General Meeting And Annual Report For The FY 2023-24 Notice of 45th Annual General Meeting of the Company and Annual Report for FY 23-24. The AGM of the Company will be held on Wednesday September 18 2024 at 03:30 p.m. through Audio Visual/Other Audio Visual Means. |
| BSE 27-Aug-2024 | General Announcements FILE | Business Responsibility and Sustainability Reporting (BRSR) Pursuant to Regulation 34(2)(f) of the SEBI (Listing and Obligations & Disclosure Requirements) Regulations 2015 Please find enclosed Business Responsibility and Sustainability Reporting for financial year 2023-24. |
| BSE 27-Aug-2024 | General Announcements FILE | Reg. 34 (1) Annual Report. Pursuant to Regulation 30 and 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (Listing Regulations) please find enclosed the Annual Report and Notice convening the 45th Annual General Meeting of the Company including the Business Responsibility and Sustainability Report for the financial year 2023-24 which is scheduled to be held on Wednesday September 18 2024 at 03:30 p.m. (IST) through video conference or other audio-visual means (VC/OAVM) in compliance with relevant circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India (SEBI). |
INSIDER TRADING FOR JAGSONPAL PHARMACEUTICALS
| Exchange Dates | Activity | Qty & Price (%) | Person / Organisation |
|---|---|---|---|
| BSE 27-Jun-2022 27-Jun-2022 | Sell Off Market | 11,455,500 @ 0.00 (43.74 %) | Rajpal Singh Kochhar for and on behalf of Aresko Progressive Pvt Ltd acting in capacity as a trustee of the Aresko Progressive Trust; and as the representative partner of J&P Investments Partnership |
| BSE 25-Feb-2022 25-Feb-2022 | Sell Market | 225,737 @ 0.00 (0.86 %) | Rajpal Singh Kochhar for and on behalf of Aresko Progressive Pvt Ltd acting in capacity as a trustee of the Aresko Progressive Trust and as the representative partner of J&P Investments Partnership |
| BSE 24-Feb-2022 24-Feb-2022 | Sell Market | 199,763 @ 0.00 (0.77 %) | Rajpal Singh Kochhar for and on behalf of Aresko Progressive Pvt Ltd acting in capacity as a trustee of the Aresko Progressive Trust and as the representative partner of J&P Investments Partnership |
BULK BLOCK DEALS FOR JAGSONPAL PHARMACEUTICALS LIMITED
| Exchange Dates | Activity | Qty & Price (%) | Person / Organisation |
|---|---|---|---|
| No Bulk Block details found | |||
DIVIDEND BY JAGSONPAL PHARMACEUTICALS LIMITED
| Ex Dividend Date | Dividend Type | Dividend |
|---|---|---|
| 06-Sep-2024 | DIVIDEND | 5 |
| 21-Aug-2023 | DIVIDEND | 5 |
| 29-Oct-2021 | INTERIM DIVIDEND | 4 |
| 22-Sep-2021 | DIVIDEND | 1 |
SPLIT / BONUS BY JAGSONPAL PHARMACEUTICALS LIMITED
| Ex Date | Type | Detail |
|---|---|---|
| 08-Jan-2025 | SPLIT | Rs 5 to Rs 2 |
Data feed Source : www.accordfintech.com, NSE DATA Feed & BSE Data Feed
